The ICER Process: Allergan Engagement Improves Cost Effectiveness Rating For Ubrelvy
Executive Summary
ICER president Steve Pearson is ‘cautiously optimistic’ that net pricing for acute migraine treatments will align with benefits once discounts are factored in.
You may also be interested in...
Lilly, Allergan Beat Biohaven To Acute Migraine Market With Reyvow, Ubrelvy Launches
After DEA scheduling, Reyvow will be available at pharmacies soon with a list price of $640 for eight tablets. Allergan confirmed that its drug is at pharmacies and prescriptions are being filled.
ICER Will Assess Real World Evidence On Accelerated Approvals After Two Years
Process will incorporate real world evidence into future cost effectiveness updates of already reviewed drugs to supplement the information available prior to launch.
Drug Pricing Avoids The Limelight During State Of The Union Address
President Trump did not offer any new proposals on drug pricing during an evening featuring campaign theatrics on both sides.
Need a specific report? 1000+ reports available
Buy Reports